羟苯磺酸钙胶囊联合替米沙坦对2型糖尿病肾病的疗效观察及分析

摘要

目的 探讨应用羟苯磺酸钙联合替米沙坦这两种药物治疗2型糖尿病肾病的临床效果. 方法 选取该院于2014年1月—2015年5月期间所收治的2型糖尿病肾病患者60例作为该次研究的对象,根据治疗方法的不同将患者以实验组和对照组进行划分,每组各30例. 两组患者均接受常规降血糖治疗和低蛋白饮食,实验组采用口服羟苯磺酸钙胶囊联合替米沙坦治疗,对照组单用替米沙坦治疗. 比较两组患者治疗前后血肌酐(Scr)、血尿素氮(BUN)、尿白蛋白排泄率 (UAER)以及糖化血红蛋白(HbA1c)水平变化情况. 结果 经过持续12个星期治疗后,发现两组患者治疗前后Scr、BUN水平变化比较差异无统计学意义(P>0.05);两组患者治疗后UAER水平与治疗之前比较均有显著改善,差异有统计学意义(P<0.05);两组患者治疗前后HbA1c水平比较差异无统计学意义(P>0.05). 治疗后实验组UAER水平改善情况优于对照组,差异有统计学意义(P<0.05);治疗后实验组与对照组HbA1c水平比较差异无统计学意义(P>0.05).结论 临床应用羟苯磺酸钙联合替米沙坦这两种药物治疗2型糖尿病肾病能有效降低患者的尿白蛋白排泄率, 具有较高的安全性,值得推广借鉴.%Objective To explore the application of calcium dobesilate combined with telmisartan in the two drug treatment of type 2 diabetic nephropathy clinical effect. Methods 2 diabetic nephropathy patients in our hospital from January 2014 to May 2015 were selected as the object of this study, according to different treatment methods, patients in the experimental group and the control group were divided into 30 cases in each group. Two groups of patients were treated with conventional hypoglycemic therapy and low protein diet, the experimental group with oral calcium dobesilate capsule combined with telmisartan treatment, and the patients in control group were treated with telmisartan alone. Blood creatinine (Scr), blood urea nitrogen (BUN), urinary albumin excretion rate (UAER) and glycosylated hemoglobin (HbA1c) levels were compared between the two groups. Results after 12 weeks of treatment, there was no significant difference in BUN and Scr levels be-tween the two groups before and after treatment (P >0.05);the difference was statistically significant (P <0.05);the differ-ence was not statistically significant (P> 0.05) before and after treatment in two groups. After treatment, the UAER level of the experimental group was better than the control group, the difference was statistically significant (P <0.05);there was no significant difference between the experimental group and the control group (P >0.05). Conclusion The clinical application of calcium dobesilate combined with telmisartan in the two drug treatment of type 2 diabetic nephropathy can effectively re-duce the rate of urinary albumin excretion in patients, with high security, it is worth learning to promote.